Seres Therapeutics (NASDAQ:MCRB) Trading Down 2.2%

Seres Therapeutics, Inc. (NASDAQ:MCRBGet Rating)’s share price fell 2.2% during mid-day trading on Friday . The company traded as low as $6.55 and last traded at $6.56. 17,300 shares were traded during mid-day trading, a decline of 98% from the average session volume of 722,382 shares. The stock had previously closed at $6.71.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MCRB. Chardan Capital dropped their target price on shares of Seres Therapeutics from $16.00 to $12.00 in a report on Thursday, August 4th. Piper Sandler increased their target price on shares of Seres Therapeutics from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Wednesday. Jefferies Financial Group raised shares of Seres Therapeutics to a “buy” rating in a report on Wednesday, June 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Seres Therapeutics in a report on Wednesday, June 8th.

Seres Therapeutics Stock Down 3.9 %

The firm’s 50-day moving average price is $4.72 and its 200 day moving average price is $5.01. The firm has a market capitalization of $800.25 million, a price-to-earnings ratio of -5.66 and a beta of 3.03. The company has a debt-to-equity ratio of 2.20, a current ratio of 2.35 and a quick ratio of 2.35.

Seres Therapeutics (NASDAQ:MCRBGet Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The business had revenue of $1.22 million during the quarter, compared to analyst estimates of $6.03 million. Seres Therapeutics had a negative net margin of 75.48% and a negative return on equity of 100.32%. Sell-side analysts expect that Seres Therapeutics, Inc. will post -2.12 EPS for the current year.

Insider Activity

In other news, major shareholder Health Ltp Fund Ge Nutritional bought 8,738,243 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The shares were purchased at an average price of $3.15 per share, for a total transaction of $27,525,465.45. Following the completion of the transaction, the insider now owns 5,875,711 shares in the company, valued at $18,508,489.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Seres Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Teacher Retirement System of Texas boosted its position in Seres Therapeutics by 23.0% during the fourth quarter. Teacher Retirement System of Texas now owns 13,562 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 2,536 shares during the last quarter. Credit Suisse AG raised its stake in Seres Therapeutics by 4.1% during the second quarter. Credit Suisse AG now owns 90,359 shares of the biotechnology company’s stock worth $309,000 after purchasing an additional 3,532 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Seres Therapeutics by 54.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,668 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 3,775 shares during the period. Strs Ohio raised its stake in Seres Therapeutics by 4.2% during the first quarter. Strs Ohio now owns 102,800 shares of the biotechnology company’s stock worth $731,000 after purchasing an additional 4,100 shares during the period. Finally, E Fund Management Co. Ltd. raised its stake in Seres Therapeutics by 38.4% during the first quarter. E Fund Management Co. Ltd. now owns 14,871 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 4,127 shares during the period. Institutional investors and hedge funds own 96.09% of the company’s stock.

About Seres Therapeutics

(Get Rating)

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

Featured Stories

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.